FY2018 EPS Estimates for Bristol-Myers Squibb Decreased by William Blair (BMY)

Bristol-Myers Squibb (NYSE:BMY) – Analysts at William Blair cut their FY2018 earnings estimates for Bristol-Myers Squibb in a research report issued on Tuesday, April 17th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $3.18 for the year, down from their prior forecast of $3.21. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Bristol-Myers Squibb’s Q4 2018 earnings at $0.76 EPS, Q1 2019 earnings at $0.83 EPS, Q2 2019 earnings at $0.85 EPS, Q3 2019 earnings at $0.88 EPS, Q4 2019 earnings at $0.90 EPS, FY2019 earnings at $3.46 EPS and FY2020 earnings at $4.11 EPS.

How to Become a New Pot Stock Millionaire

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.63 EPS.

A number of other equities analysts have also weighed in on BMY. Jefferies Group restated a “hold” rating and issued a $66.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, April 13th. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Tuesday. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $51.00 to $47.00 and set an “underperform” rating on the stock in a research note on Wednesday. Bank of America reduced their price objective on Bristol-Myers Squibb from $68.00 to $61.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, Morgan Stanley lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $54.08 to $58.00 in a research report on Tuesday. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $64.51.

Shares of NYSE BMY opened at $52.30 on Wednesday. The stock has a market capitalization of $88,290.09, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 1.41 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb has a twelve month low of $51.56 and a twelve month high of $70.05.

Hedge funds have recently modified their holdings of the stock. Delphi Private Advisors LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $108,000. Massey Quick Simon & CO. LLC lifted its holdings in Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the period. Horan Capital Advisors LLC. purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth approximately $122,000. NuWave Investment Management LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $119,000. Finally, AllSquare Wealth Management LLC purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth approximately $134,000. Institutional investors own 71.51% of the company’s stock.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.06%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

COPYRIGHT VIOLATION NOTICE: This article was reported by Week Herald and is owned by of Week Herald. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://weekherald.com/2018/04/19/fy2018-eps-estimates-for-bristol-myers-squibb-decreased-by-william-blair-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply